The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
Abstract
Background: Clinical predictors of advanced non-alcoholic liver disease (NAFLD) are needed to guide diagnostic evaluation and treatment. Methods: To better understand the demographics of NAFLD and risk factors for advanced disease, this study analysed 827 patients with NAFLD at two geographically separate tertiary medical centres. Results: The cohort was 51% female and had a median body mass index (BMI) of 33 kg/m 2 ; 3% had a normal BMI. Common co-morbidities included hypertension (60%) and diabetes (35%); insulin resistance was present in 91% and advanced fibrosis in 24% of patients. When comparing patients with no fibrosis or mild fibrosis to those with advanced fibrosis, BMI ⩾28 kg/m 2 , age >50 years, and aspartate transaminase/alanine aminotransferase (AST/ALT) ratio ⩾0.8, a quantitative assessment check index (QUICKI) score <0.294 (equivalent to homeostatasis model assessment (HOMA) >6.2) and the presence of diabetes mellitus (DM) were individually associated by univariate analysis with odds ratios (ORs) of ⩾2.4 for advanced fibrosis. Based on the results of forced entry logistic regression analysis, three variables were combined in a weighted sum ( B MI ⩾28 = 1 point, A AR of ⩾0.8 = 2 points, D M = 1 point) to form an easily calculated composite score for predicting advanced fibrosis called the BARD score. A score of 2–4 was associated with an OR for advanced fibrosis of 17 (confidence interval 9.2 to 31.9) and a negative predictive value of 96%. Conclusions: Insulin resistance and its co-morbidities are often present in patients with NAFLD. An easily calculated score based on readily available clinical data can reliably exclude the presence of advanced fibrosis in these patients, particularly among non-diabetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Self-citationPrevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445
Dixon, J. B., Bhathal, P. S., & O'Brien, P. E. (2001) · Gastroenterology · doi:10.1053/gast.2001.25540 · Cited by 1,360
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191
Cited by
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
“Several other scores or algorithms have been proposed in hepatitis C virus (HCV) [22–35], as well as in hepatitis B virus (HBV) [36,37], human immunodeficiency virus (HIV)-HCV coinfection [38,39], and NAFLD [40,41].”
BackgroundSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
McPherson, S., Stewart, S. F., Henderson, E., Burt, A. D., & Day, C. P. (2010) · Gut · doi:10.1136/gut.2010.216077 · Cited by 946
Xiao, G., Zhu, S., Xiao, X., Yan, L., Yang, J., & Wu, G. (2017) · Hepatology · doi:10.1002/hep.29302 · Cited by 895
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W.-S., Nobili, V., Day, C. P., Sookoian, S., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander-Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 818
Self-citationImajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., Fujita, K., Yoneda, M., Taguri, M., Hyogo, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.048 · Cited by 812
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L. M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.005 · Cited by 804
Sumida, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.475 · Cited by 689
Wong, V. W.-S., Wong, G. L.-H., Choi, P. C.-L., Chan, A. W.-H., Li, M. K.-P., Chan, H.-Y., Chim, A. M.-L., Yu, J., Sung, J. J.-Y., & Chan, H. L.-Y. (2010) · Gut · doi:10.1136/gut.2009.205088 · Cited by 648
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W.-S., Adams, L. A., de Lédinghen, V., Wong, G. L.-H., & Sookoian, S. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 614
Vilar-Gomez, E., & Chalasani, N. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.013 · Cited by 610
Vuppalanchi, R., & Chalasani, N. (2009) · Hepatology · doi:10.1002/hep.22603 · Cited by 563
Angulo, P., Bugianesi, E., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Barrera, F., Haflidadottir, S., Day, C. P., & George, J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.06.057 · Cited by 502
Wong, V. W.-S., Chu, W. C.-W., Wong, G. L.-H., Chan, R. S.-M., Chim, A. M.-L., Ong, A., Yeung, D. K.-W., Yiu, K. K.-L., Chu, S. H.-T., Woo, J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300342 · Cited by 491
Pathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.21 · Cited by 484
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470
Self-citationClinical, Laboratory and Histological Associations in Adults with Nonalcoholic Fatty Liver Disease†
Neuschwander-Tetri, B. A., Clark, J. M., Bass, N. M., Van Natta, M. L., Unalp-Arida, A., Tonascia, J., Zein, C. O., Brunt, E. M., Kleiner, D. E., McCullough, A. J., et al. (2010) · Hepatology · doi:10.1002/hep.23784 · Cited by 463
Self-citationNon-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal
Machado, M. V., & Cortez-Pinto, H. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.021 · Cited by 412
Kwok, R., Tse, Y. ‐., Wong, G. L. ‐., Ha, Y., Lee, A. U., Ngu, M. C., Chan, H. L. ‐., & Wong, V. W. ‐. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12569 · Cited by 405
Boursier, J., Vergniol, J., Guillet, A., Hiriart, J.-B., Lannes, A., Le Bail, B., Michalak, S., Chermak, F., Bertrais, S., Foucher, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.023 · Cited by 400
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study
Loomba, R., Schork, N., Chen, C.-H., Bettencourt, R., Bhatt, A., Ang, B., Nguyen, P., Hernandez, C., Richards, L., Salotti, J., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.011 · Cited by 389
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Aoki, N., Kanemasa, K., et al. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-2 · Cited by 383
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100403 · Cited by 357
Nonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 345
Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action
Bril, F., & Cusi, K. (2017) · Diabetes Care · doi:10.2337/dc16-1787 · Cited by 341
Lee, Y.-H., Jung, K. S., Kim, S. U., Yoon, H.-J., Yun, Y. J., Lee, B.-W., Kang, E. S., Han, K.-H., Lee, H. C., & Cha, B.-S. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.051 · Cited by 340
Muzurović, E., Mikhailidis, D. P., & Mantzoros, C. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154770 · Cited by 336
Balakrishnan, M., Patel, P., Dunn-Valadez, S., Dao, C., Khan, V., Ali, H., El-Serag, L., Hernaez, R., Sisson, A., Thrift, A. P., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.067 · Cited by 324
Wei, J. L., Leung, J. C.-F., Loong, T. C.-W., Wong, G. L.-H., Yeung, D. K.-W., Chan, R. S.-M., Chan, H. L.-Y., Chim, A. M.-L., Woo, J., Chu, W. C.-W., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.235 · Cited by 318
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04556.x · Cited by 312
Armstrong, M. J., Houlihan, D. D., Bentham, L., Shaw, J. C., Cramb, R., Olliff, S., Gill, P. S., Neuberger, J. M., Lilford, R. J., & Newsome, P. N. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.020 · Cited by 300
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.021 · Cited by 294
Yang, J., Fernández-Galilea, M., Martínez-Fernández, L., González-Muniesa, P., Pérez-Chávez, A., Martínez, J. A., & Moreno-Aliaga, M. J. (2019) · Nutrients · doi:10.3390/nu11040872 · Cited by 292
Non-alcoholic fatty liver disease
Smith, B. W., & Adams, L. A. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.596521 · Cited by 285
Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.327 · Cited by 280
Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz-Lopez, C., Hecht, J., Feldstein, A. E., Webb, A., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.042 · Cited by 273
Self-citationNoninvasive evaluation of NAFLD
Castera, L., Vilgrain, V., & Angulo, P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.175 · Cited by 273
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 268
Self-citationKASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Kang, S. H., Lee, H. W., Yoo, J.-J., Cho, Y., Kim, S. U., Lee, T. H., Jang, B. K., Kim, S. G., Ahn, S. B., Kim, H., et al. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0178 · Cited by 267
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches
Schuppan, D., & Schattenberg, J. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12212 · Cited by 256
Harrison, S. A., Ratziu, V., Boursier, J., Francque, S., Bedossa, P., Majd, Z., Cordonnier, G., Sudrik, F. B., Darteil, R., Liebe, R., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30252-1 · Cited by 255
Self-citationMetabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
Lee, H.-H., Lee, H. A., Kim, E.-J., Kim, H. Y., Kim, H. C., Ahn, S. H., Lee, H., & Kim, S. U. (2024) · Gut · doi:10.1136/gutjnl-2023-331003 · Cited by 254
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
McMahan, R. H., Wang, X. X., Cheng, L. L., Krisko, T., Smith, M., El Kasmi, K., Pruzanski, M., Adorini, L., Golden-Mason, L., Levi, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.446575 · Cited by 225
Impact of non-invasive biomarkers on hepatology practice: past, present and future
Anstee, Q. M., Castera, L., & Loomba, R. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.03.026 · Cited by 224
Younes, R., Caviglia, G. P., Govaere, O., Rosso, C., Armandi, A., Sanavia, T., Pennisi, G., Liguori, A., Francione, P., Gallego-Durán, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.008 · Cited by 196
Hagström, H., Talbäck, M., Andreasson, A., Walldius, G., & Hammar, N. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.008 · Cited by 182
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
De Vincentis, A., Tavaglione, F., Jamialahmadi, O., Picardi, A., Antonelli Incalzi, R., Valenti, L., Romeo, S., & Vespasiani-Gentilucci, U. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.05.056 · Cited by 158
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140
Hagström, H., Nasr, P., Ekstedt, M., Stål, P., Hultcrantz, R., & Kechagias, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.11.030 · Cited by 132
“5) 72/228 (32) 49/228 (21) High 12/30 (40) 3 (10.”
Serum Immunoglobulin Levels Predict Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease
McPherson, S., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.010 · Cited by 124
Świderska, M., Maciejczyk, M., Zalewska, A., Pogorzelska, J., Flisiak, R., & Chabowski, A. (2019) · Free Radical Research · doi:10.1080/10715762.2019.1635691 · Cited by 107
“BMI and BARD score were also calculated [5].”
BackgroundMethodInfluentialNonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Galvin, Z., Rajakumar, R., Chen, E., Adeyi, O., Selzner, M., Grant, D., Sapisochin, G., Greig, P., Cattral, M., McGilvray, I., et al. (2019) · Liver Transplantation · doi:10.1002/lt.25338 · Cited by 76
Eslam, M., Wong, G. L.-H., Hashem, A. M., Chan, H. L.-Y., Nielsen, M. J., Leeming, D. J., Chan, A. W.-H., Chen, Y., Duffin, K. L., Karsdal, M., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001059 · Cited by 53
Lavynenko, O., Abdul‐Ghani, M., Alatrach, M., Puckett, C., Adams, J., Abdelgani, S., Alkhouri, N., Triplitt, C., Clarke, G. D., Vasquez, J. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14650 · Cited by 44
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022) · Hormones · doi:10.1007/s42000-022-00377-8 · Cited by 39
Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date
Albhaisi, S., & Sanyal, A. J. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00305-z · Cited by 27
Furuya, S., Manabe, O., Ohira, H., Hirata, K., Aikawa, T., Naya, M., Tsujino, I., Koyanagawa, K., Anzai, T., Oyama-Manabe, N., et al. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0447-8 · Cited by 27
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02408-7 · Cited by 17
“The FLI and BARD scores are frequently measured in clinical practice and can predict hepatic steatosis and fibrosis with acceptable performance in the general population [11–13].”
BackgroundMethodZhyzhneuskaya, S. V., Al‐Mrabeh, A. H., Peters, C., Barnes, A. C., Hollingsworth, K. G., Welsh, P., Sattar, N., Lean, M. E. J., & Taylor, R. (2025) · Diabetic Medicine · doi:10.1111/dme.15462 · Cited by 6
Metadata
- Authors
- Harrison, S. A., Oliver, D., Arnold, H. L., Gogia, S., & Neuschwander-Tetri, B. A.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2008-04-04
- Volume
- 57
- Issue
- 10
- Pages
- 1441-1447
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2171172585
- Cited by
- 869
- References
- 46
- FWCI
- 19.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.